Vyriad, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2016-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.vyriad.com
Phase 2 Trial of Voyager V1 in Combination with Cemiplimab in Cancer Patients
Phase 2
Recruiting
- Conditions
- Head and Neck Squamous Cell CarcinomaColo-rectal CancerMelanoma
- Interventions
- Biological: VV1
- First Posted Date
- 2020-03-02
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Vyriad, Inc.
- Target Recruit Count
- 87
- Registration Number
- NCT04291105
- Locations
- 🇺🇸
Mayo Clinical, Jacksonville, Florida, United States
🇺🇸City of Hope Medical Center, Durate, California, United States
🇺🇸USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors
Phase 1
Recruiting
- Conditions
- Solid TumorNon Small Cell Lung CancerNeuroendocrine CarcinomaRenal Cell Carcinoma (RCC)
- Interventions
- First Posted Date
- 2018-08-27
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Vyriad, Inc.
- Target Recruit Count
- 86
- Registration Number
- NCT03647163
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States
Trial of Intravesical Measles Virotherapy in Patients With Bladder Cancer Who Are Undergoing Radical Cystectomy
Phase 1
Completed
- Conditions
- Urothelial Carcinoma
- Interventions
- Biological: MV-NIS
- First Posted Date
- 2017-05-31
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- Vyriad, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT03171493
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Ochsner Health, New Orleans, Louisiana, United States
Ph1 Administration of VSV-IFNβ-NIS Monotherapy and in Combination With Avelumab in Pts With Refractory Solid Tumors
Phase 1
Completed
- Conditions
- Malignant Solid Tumour
- Interventions
- Biological: VSV-IFNβ-NIS and avelumabBiological: VSV-IFNβ-NIS
- First Posted Date
- 2016-10-04
- Last Posted Date
- 2022-04-27
- Lead Sponsor
- Vyriad, Inc.
- Target Recruit Count
- 76
- Registration Number
- NCT02923466
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸Mary Crowley Cancer Research Center, Dallas, Texas, United States
🇺🇸Sanford Cancer Center, Sioux Falls, South Dakota, United States
Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With Atezolizumab
Phase 1
Terminated
- Conditions
- Recurrent Non-Small Cell Lung Cancer
- Interventions
- Biological: MV-NISBiological: Atezolizumab
- First Posted Date
- 2016-09-29
- Last Posted Date
- 2023-07-21
- Lead Sponsor
- Vyriad, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT02919449
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States